New Analysis Demonstrates Successful Reduction or Withdrawal of Standard of Care Therapies in Patients Treated with Aficamten SOUTH SAN FRANCISCO, Calif., Sept. 30, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today presented new data on the reduction and withdrawal of background standard of care medical therapy in patients treated […]
Tag: Cytokinetics
Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program
Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases Deadline for Applications is November 11th, 2022 SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the fifth […]
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 31, 2022 it granted stock options to purchase an aggregate of 186,400 shares of common stock to 23 new employees, whose employment commenced in August 2022, as a material inducement to […]
Cytokinetics Reports Second Quarter 2022 Financial Results
Advisory Committee Meeting to Review NDA for Omecamtiv Mecarbil Scheduled for December 13, 2022; PDUFA Target Action Date Set for February 28, 2023 Company Revises 2022 Financial Guidance; Reduces Projected Spending for 2022 SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for […]
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 29, 2022 it granted stock options to purchase an aggregate of 88,200 shares of common stock to 11 new employees, whose employment commenced in July 2022, as a material inducement to […]
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
SOUTH SAN FRANCISCO, Calif., July 05, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 30, 2022 it granted stock options to purchase an aggregate of 180,450 shares of common stock to 19 new employees, whose employment commenced in June 2022, as a material inducement to […]
Cytokinetics Announces Proposed Convertible Senior Notes Offering
SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced its intention to offer, subject to market and other conditions, $450.0 million aggregate principal amount of convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant to […]
Cytokinetics Provides Regulatory Update for Omecamtiv Mecarbil
Recent Company Submission in Response to FDA Request Extends PDUFA Date SOUTH SAN FRANCISCO, Calif., June 17, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that, in response to a request from the U.S. Food and Drug Administration (FDA), the company recently provided additional pharmacokinetic analyses of omecamtiv mecarbil related […]
Cytokinetics Announces Additional Data From REDWOOD-HCM Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions
Echocardiographic Data Show Treatment with Aficamten for 10 Weeks Results In Improved Cardiac Structure, Myocardial Relaxation and Mitral Valve Mechanics SOUTH SAN FRANCISCO, Calif., June 13, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from a new analysis of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM) […]
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 31, 2022 it granted stock options to purchase an aggregate of 179,100 shares of common stock to 23 new employees, whose employment commenced in May 2022, as a material inducement to […]
Recent
Ancora Heart Inc. Reports Two-Year Results Demonstrating Sustained Benefits of AccuCinch® System in Heart Failure Patients
Cardiawave Strengthens Leadership with Appointment of Jonathan Freeman as Board Chairman
AngioInsight Appoints Medtech Veteran Shlomi Nachman to Board of Directors; Announces Series A Round to Accelerate AI-Driven Advancement in Cardiology
Popular
- No commented posts yet